Acm Medical Laboratory INC

Acm Medical Laboratory INC was paid $40.84M by Medicaid between Jan 2018 and Dec 2021, across 266 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 31% of everything it billed.

33Billing provider infoACM MEDICAL LABORATORY INC
ROCHESTER, NY 14624

33aNPI1174517353assigned 09/02/2005

33bProvider typeClinical Medical Laboratory

28Total paid$40.84M

24GClaims1,995,256

24DCodes billed266

24AFirst – last monthJan 2018 – Dec 2021

Compared with peers

Next to other Clinical Medical Laboratory providers in New York

Rank by total paid#10 of 116

Median peer was paid$618K

This provider vs. median66×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	656,280	$14.22M
2019	716,918	$13.96M
2020	610,819	$12.39M
2021	11,239	$276K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	31%	364,436	172,749	$12.64M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	18%	138,574	70,236	$7.48M
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	6.4%	28,326	26,493	$2.60M
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	5.2%	74,801	73,131	$2.14M
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	5.2%	74,090	72,421	$2.12M
87480		2.0%	46,251	44,907	$803K
87660		2.0%	46,072	44,731	$798K
87510		1.9%	45,835	44,502	$795K
87631		1.8%	6,679	6,503	$732K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	1.7%	25,955	25,796	$679K
80061	Lipid panel	1.4%	53,483	53,109	$577K
84443	Thyroid stimulating hormone (TSH)	1.4%	44,170	43,610	$565K

254 more codes

80053	Comprehensive metabolic panel	1.3%	58,555	$525K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	1.2%	24,959	$476K
80050	General health panel	<1%	13,455	$402K
87086	Culture, bacterial; quantitative colony count, urine	<1%	50,663	$361K
83036	Hemoglobin; glycosylated (A1C)	<1%	42,133	$359K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	45,177	$248K
86780		<1%	21,115	$243K
81220	CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants	<1%	529	$242K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	2,529	$195K
82607		<1%	15,230	$184K
80048	Basic metabolic panel (calcium, ionized)	<1%	28,428	$184K
85027		<1%	36,189	$180K
80348		<1%	46,571	$159K
87081		<1%	26,599	$156K
84439		<1%	19,943	$155K
87077		<1%	18,087	$153K
84702		<1%	10,350	$135K
86481		<1%	2,403	$133K
82728		<1%	10,419	$120K
87653		<1%	3,616	$113K
83655		<1%	9,499	$109K
86803		<1%	9,051	$107K
87070		<1%	13,211	$100K
83970		<1%	2,834	$99K
80349		<1%	29,366	$96K
87186		<1%	13,041	$95K
87505		<1%	1,057	$90K
80074		<1%	2,312	$84K
80346		<1%	24,158	$83K
87340		<1%	9,082	$82K
80323		<1%	25,801	$82K
84403		<1%	3,483	$81K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	2,866	$75K
81507		<1%	134	$74K
86762		<1%	7,085	$73K
84153		<1%	4,451	$71K
87522	Neg quan hep c or qual rna	<1%	1,642	$65K
83550		<1%	9,489	$63K
82746		<1%	5,723	$63K
80076		<1%	9,271	$61K
87088		<1%	7,819	$58K
81001		<1%	20,150	$57K
83540		<1%	10,861	$56K
88142		<1%	2,635	$55K
82570		<1%	25,762	$54K
85610		<1%	16,833	$53K
87252		<1%	2,109	$50K
86038		<1%	5,193	$50K
86706		<1%	5,337	$49K
82043		<1%	10,445	$49K
80350		<1%	23,184	$49K
86696		<1%	2,971	$48K
84146		<1%	2,636	$47K
84480		<1%	3,951	$45K
83520		<1%	2,519	$44K
84402		<1%	1,931	$44K
83001		<1%	2,629	$44K
86003		<1%	1,021	$43K
80324		<1%	12,857	$43K
82670		<1%	1,608	$39K
83880		<1%	1,579	$36K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	1,437	$36K
86850		<1%	4,974	$34K
86235		<1%	1,022	$32K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	1,096	$32K
82105		<1%	2,215	$31K
86140		<1%	8,852	$31K
83020		<1%	2,259	$30K
87536		<1%	381	$29K
85652		<1%	12,857	$28K
84163		<1%	2,098	$28K
83735		<1%	5,396	$27K
86765		<1%	2,697	$26K
83002		<1%	1,559	$26K
87254		<1%	348	$25K
84425		<1%	1,414	$25K
86160		<1%	1,207	$24K
86704		<1%	2,369	$24K
80353		<1%	7,778	$23K
86787		<1%	2,643	$23K
86735		<1%	2,458	$22K
86141		<1%	1,979	$22K
80069		<1%	3,020	$21K
83690		<1%	3,730	$21K
86708		<1%	1,993	$20K
84703		<1%	3,572	$20K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	803	$19K
82950		<1%	4,597	$19K
82784		<1%	1,680	$19K
86901		<1%	6,600	$18K
86376		<1%	1,425	$18K
83921		<1%	1,140	$17K
86431		<1%	3,383	$17K
86665		<1%	723	$15K
84144		<1%	837	$15K
87902		<1%	66	$15K
86695		<1%	1,642	$15K
86200		<1%	1,314	$15K
87338		<1%	1,182	$14K
86618		<1%	1,287	$14K
82150		<1%	2,701	$14K
82627		<1%	703	$14K
82274		<1%	1,426	$13K
86900		<1%	4,846	$13K
84550		<1%	3,596	$13K
82533		<1%	869	$13K
82525		<1%	1,091	$12K
84481		<1%	981	$12K
87101		<1%	1,637	$12K
86709		<1%	1,248	$12K
80164		<1%	1,081	$11K
82677		<1%	551	$11K
83525		<1%	1,022	$11K
86225		<1%	954	$11K
88141		<1%	838	$10K
82785		<1%	675	$10K
84630		<1%	1,110	$10K
82550		<1%	1,815	$10K
83516		<1%	695	$10K
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	572	$9K
86800		<1%	774	$9K
84156		<1%	2,751	$9K
86256		<1%	742	$9K
87046		<1%	449	$9K
36415	Collection of venous blood by venipuncture	<1%	8,743	$9K
85014		<1%	4,179	$9K
83090		<1%	566	$8K
82977		<1%	1,438	$8K
87209		<1%	607	$8K
84460		<1%	2,216	$8K
83615		<1%	1,472	$7K
86255		<1%	687	$7K
82951		<1%	750	$7K
80364		<1%	3,489	$7K
86336		<1%	506	$7K
81003		<1%	13,847	$7K
87272		<1%	675	$7K
84207		<1%	273	$7K
80178		<1%	1,175	$7K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	108	$7K
86039		<1%	719	$6K
82952		<1%	748	$6K
86664		<1%	601	$6K
82947		<1%	1,869	$6K
80362		<1%	3,305	$6K
82465		<1%	1,616	$6K
86147		<1%	151	$6K
84450		<1%	1,814	$6K
86663		<1%	627	$6K
83013		<1%	104	$6K
87253		<1%	376	$6K
86360		<1%	139	$6K
84152		<1%	338	$5K
80361		<1%	1,214	$5K
82565		<1%	1,346	$5K
87102		<1%	639	$5K
87177		<1%	612	$5K
80320		<1%	1,098	$5K
85730		<1%	840	$5K
87449		<1%	524	$4K
84681		<1%	238	$4K
83721		<1%	531	$4K
83993		<1%	267	$4K
86308		<1%	862	$4K
87045		<1%	452	$4K
84466		<1%	354	$4K
84478		<1%	755	$4K
87427		<1%	308	$4K
80321		<1%	623	$3K
84100		<1%	980	$3K
83789		<1%	621	$3K
84165		<1%	296	$3K
85018		<1%	1,533	$3K
85045		<1%	883	$3K
80358		<1%	1,723	$3K
87107		<1%	441	$3K
81050		<1%	699	$3K
84436		<1%	472	$3K
87109		<1%	180	$3K
84590		<1%	251	$3K
83630		<1%	190	$3K
84446		<1%	194	$2K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	27	$2K
86021		<1%	168	$2K
87075		<1%	259	$2K
80325		<1%	649	$2K
87269		<1%	214	$2K
87350		<1%	205	$2K
83498		<1%	77	$2K
86359		<1%	58	$2K
86694		<1%	219	$2K
84132		<1%	510	$2K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	48	$2K
86707		<1%	185	$2K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	66	$2K
82390		<1%	184	$2K
84520		<1%	515	$1K
84597		<1%	122	$1K
82088		<1%	40	$1K
86592		<1%	503	$1K
82397		<1%	159	$1K
84134		<1%	132	$1K
86703		<1%	108	$1K
82103		<1%	106	$1K
87040		<1%	106	$1K
87324		<1%	130	$1K
80365		<1%	708	$986.75
86146		<1%	27	$980.18
87517		<1%	27	$940.46
86304		<1%	52	$935.92
82340		<1%	165	$866.15
84155		<1%	316	$860.28
86682		<1%	81	$803.53
87205		<1%	274	$787.34
87493		<1%	28	$782.99
86617		<1%	55	$750.29
84445		<1%	25	$734.31
82310		<1%	169	$710.16
87106		<1%	56	$691.20
80299		<1%	38	$672.29
81015		<1%	333	$605.73
86677		<1%	52	$554.25
86777		<1%	61	$554.00
87220		<1%	149	$516.40
86593		<1%	132	$474.64
80156		<1%	40	$433.23
82330		<1%	39	$412.12
87300		<1%	33	$405.30
80356		<1%	104	$400.00
G0328	Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous	<1%	26	$365.24
86705		<1%	38	$363.83
86644		<1%	40	$355.17
80177		<1%	28	$262.88
86334		<1%	13	$229.69
82378		<1%	15	$229.08
80047		<1%	26	$184.59
82040		<1%	53	$180.21
83835		<1%	12	$179.54
84075		<1%	51	$178.48
84244		<1%	12	$173.07
83986		<1%	616	$168.19
80354		<1%	282	$165.60
87110		<1%	12	$165.15
80171		<1%	12	$145.50
86645		<1%	16	$138.94
80345		<1%	43	$135.00
86063		<1%	26	$98.63
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	14	$96.26
87184		<1%	13	$90.85
85378		<1%	12	$78.63
84300		<1%	15	$64.30
80371		0%	48	$0.00
80355		0%	1,308	$0.00
83992		0%	139	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialRAMACHANDRAN, GITA (CHIEF FINANCIAL OFFICER)

Same official

Other billing entities under RAMACHANDRAN, GITA

Full network →

Provider	Location	Paid
Acm Global Laboratories LLC	Norwalk, CT	$106K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.